WE CLAIM:

1. A stable pharmaceutical composition comprising a core, wherein the core includes rabeprazole and at least 10% w/w of low viscosity hydroxypropylcellulose.

2. The stable pharmaceutical composition according to claim 1, wherein the core further comprises an antioxidant.

3. The stable pharmaceutical composition according to claim 1, wherein the viscosity of the low viscosity hydroxypropylcellulose ranges from about 5 m. Pas to about 300 m. Pas.

4. Cancelled

5. Amended. The stable pharmaceutical composition according to claim 2, wherein the antioxidant comprises one or both of butylated hydroxy toluene and butylated hydroxy anisole.

6. The stable pharmaceutical composition according to claim 5, wherein the antioxidant comprises from about 0.02% to about 0.2% by weight of the total core weight.

7. The stable pharmaceutical composition according to claim 1, wherein the core further comprise polyvinylpyrrolidone.

8. Cancelled

9. Cancelled.

10. The stable pharmaceutical composition according to claim 7, wherein the polyvinylpyrrolidone comprises from about 0.5% to about 5% by weight of the total core weight.

11. Cancelled.

12. Cancelled.

13. The stable pharmaceutical composition according to claim 1, wherein the core is coated with a subcoat layer and an enteric coat layer.

14. Amended. The stable pharmaceutical composition according to claim 13, wherein the subcoat layer comprises one or more film forming agents comprising one or more of carageenan, ethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl

cellulose, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, polyethylene glycol, polyvinyl alcohol and xanthan gum.

15. Cancelled

16. Cancelled.

17. Amended. The stable pharmaceutical composition according to claim 13, wherein the subcoat layer includes an antioxidant.

18. Amended. The stable pharmaceutical composition according to claim 13, wherein the enteric coat layer comprises one or more enteric polymers comprising one or more of cellulose acetate phthalate, hydroxypropyl methylcellulose acetate phthalate, polyvinyl acetate phthalate, hydroxy propyl phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate; and methacrylic acid copolymers.

19. Cancelled

20. Cancelled.

21. Amended. The stable pharmaceutical composition according to claim 13, wherein one or more of the core, the subcoat layer, and the enteric layer further comprise pharmaceutically acceptable inert excipients-selected from the group consisting of binders, disintegrants, lubricants, glidants, diluents, plasticizers, opacifiers, and coloring agents.

22. Cancelled

23. A process for preparing a stable pharmaceutical composition comprising a core, the process comprising:

preparing a core by

(i) blending rabeprazole and a low viscosity hydroxypropylcellulose to form a blend, and

one or both of (ii) granulating the blend and (iii) compressing the blend to form a compact mass core, wherein the low viscosity hydroxypropylcellulose comprises at least 10% w/w of the core.

24. Amended. The process according to claim 23, further comprising coating the core with one or both of a subcoat layer and an enteric coat layer.

25. **Amended.** The process according to claim 23, further comprising blending one or more antioxidants with the rabeprazole and low viscosity hydroxypropylcellulose.

26. The process according to claim 25, wherein the antioxidant is adsorbed over a diluent.

27. **Cancelled.**

28. **Cancelled.**

29. The process according to claim 23, wherein the core is prepared by one or more of a wet granulation method, a dry granulation method, or a direct compression method.

30. **Cancelled.**

31. The process according to claim 24, wherein one or both of the subcoat layer and the enteric coat layer are applied as a solution/suspension.

32. The process according to claim 31, wherein the solution/suspension is prepared in solvents selected from the group consisting of methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, water and mixtures thereof.

33. The process according to claim 24, wherein one or both of the subcoat layer and the enteric coat layer are applied using a hot melt technique.

34. **Cancelled.**

35. **Cancelled.**

36. The process according to claim 24, wherein the viscosity of the low viscosity hydroxypropylcellulose ranges from about 5 m. Pas to about 300 m. Pas.

37. **Amended.** A method of treating digestive ulcers in a mammal by administering to the mammal a stable pharmaceutical composition of rabeprazole according to claim 1.

38. **Cancelled**

39. The method of treating of claim 37, wherein the core further comprises an antioxidant.